Business Context and Reporting Period
Cytosorbents Corp (CTS) filed an 8-K Current Report dated July 31, 2019, regarding a material definitive agreement. The company is a Delaware corporation with principal executive offices in Monmouth Junction, New Jersey, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics and Debt
- Debt Financing: The Company drew down the full $5.0 million Term B Loan under its Amended and Restated Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank.
- Success Fee: A success fee of 6.37% of the funded Term B Loan amount is payable upon the occurrence of specific stock price events.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins for the reporting period.
- Liquidity: Specific liquidity metrics are not disclosed in this filing, though the drawdown of the Term B Loan indicates an increase in cash availability.
Material Changes and Agreement Terms
The First Amendment to the Loan and Security Agreement introduced several material changes to the debt structure:
- Interest-Only Period Extension: The interest-only period for term loans is extended through April 2020. It may be further extended through October 2020 if the Borrower remains compliant with financial covenant revenue tests from the funding month through March 2020.
- Amortization Adjustments: Monthly principal amortization payments after the interest-only period will increase based on the extent that the interest-only period is extended beyond November 1, 2019.
- Subsidiary Inclusion: The agreement now explicitly includes CytoSorbents Poland SP. z.o.o., aligning its treatment with CytoSorbents Switzerland GmbH.
- Success Fee Trigger Modification: The trigger for the success fee was amended. It now requires the stock price to be at least 26.13% more than the average price of the Company's common stock for the 365-day period ending on the funding date, rather than the closing price on the funding date.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the amendment to facilitate the Term B Loan drawdown. The filing highlights the conditionality of the extended interest-only period on revenue covenant compliance. No specific forward-looking guidance or new risk factors beyond the standard debt covenants are detailed in this summary.
Investor Verification Checklist
- Verify the Company's compliance with the revenue test financial covenants required to extend the interest-only period to October 2020.
- Monitor the stock price relative to the 365-day average to assess the likelihood of triggering the 6.37% success fee.
- Review the full text of the First Amendment (Exhibit 10.1) for detailed amortization schedules post-2020.
- Confirm the operational status and financial contribution of the newly included Polish subsidiary.